Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474636 | 0.76 | AOC3 (0.60) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL474635 | 0.76 | AOC3 (0.60) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL3791186 | 0.76 | ALDH1A1 (0.40) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL1029816 | 0.74 | KMT2A (0.43) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL2556702 | 0.72 | AOC3 (0.36) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL9769938 | 0.72 | ALDH1A1 (0.42) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL15332519 | 0.71 | AOC3 (0.42) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL2209210 | 0.71 | AOC3 (0.64) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL2207915 | 0.71 | AOC3 (0.64) | KMT2AKDM4EMAPTMEN1ALDH1A1 | |
| SCHEMBL15330060 | 0.71 | AOC3 (0.35) | KMT2AKDM4EMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| CN-103755720-B | Thienopyrimidine derovatives as TRPA1 regulator | 格兰马克药品股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| EP-2708538-B1 | Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-06-04 | — | — | US | disclosed |
| EP-2342179-B1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-05-27 | — | — | EP | disclosed |
| EP-2342179-B1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-05-27 | — | — | EP | disclosed |
| US-9000159-B2 | Fused pyrimidine-dione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-8987278-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-24 | — | — | US | disclosed |
| EP-2634191-B1 | Process for preparing derivatives of thienopyrimidinedione | GLENMARK PHARMACEUTICALS SA (CH) | 2014-12-24 | — | — | EP | disclosed |
| WO-2010109334-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| WO-2010029379-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010029379-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2010-03-18 | — | — | WO | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-4202975-A | ANTIINFLAMMATORY ANALGESIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-05-13 | — | — | US | disclosed |
| US-4129654-A | Isoxazolo[3,4-d]pyrimidines useful as antiinflammatory-analgesic agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | KMT2A 4001/4885KDM4E 4699/4885MAPT 2021/4885 |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | KMT2A 2310/4885KDM4E 2687/4885MAPT 1465/4885 |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | KMT2A 2310/4885KDM4E 2687/4885MAPT 1465/4885 |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK6, MAPK4 | KMT2A 1618/4885KDM4E 1312/4885MAPT 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.